Schmoeller Deonilson, Picarelli Maria Mercedes, Paz Munhoz Terezinha, Poli de Figueiredo Carlos Eduardo, Staub Henrique Luiz
Rheumatology Department, Saint Lucas Hospital, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
Pathology Laboratory, Saint Lucas Hospital, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
Front Med (Lausanne). 2017 Sep 6;4:146. doi: 10.3389/fmed.2017.00146. eCollection 2017.
Mean platelet volume (MPV), measured using automated blood analysers, has been appraised as a potential biomarker in cardiovascular disease, diabetes mellitus, and cancer. The test, a useful tool in differentiation of thrombocytopenic states, has now been carried out for autoimmune disorders, but data are yet scarce. Controversial results have been obtained in systemic and organ-specific autoimmune disorders. Another test, the immature platelet fraction (IPF) reflects the amount of young, reticulated platelets. IPF is calculated by automated hematology analysis or flow cytometry, and it is usually high in patients with rapid platelet destruction. For both MPV and IPF, standardization of cutoff is a major need. In this review, we focus the current applicability of MPV and IPF as biomarkers in patients with autoimmune diseases.
使用自动血液分析仪测量的平均血小板体积（MPV）已被评估为心血管疾病、糖尿病和癌症的潜在生物标志物。该检测作为区分血小板减少状态的有用工具，目前已应用于自身免疫性疾病，但相关数据仍然稀缺。在系统性和器官特异性自身免疫性疾病中已获得了有争议的结果。另一项检测，未成熟血小板分数（IPF）反映了年轻的、网状血小板的数量。IPF通过自动血液学分析或流式细胞术计算得出，在血小板快速破坏的患者中通常较高。对于MPV和IPF而言，标准化临界值是一项主要需求。在本综述中，我们重点关注MPV和IPF作为自身免疫性疾病患者生物标志物的当前适用性。
